It did not take long for predictions of higher-priced merger-and-acquisition activity in 2025 to come true as Johnson & Johnson’s proposed $14.6bn buyout of Intra-Cellular and its rising neuropsychiatric drug Caplyta (lumateperone) was the largest of multiple billion-dollar plus transactions unveiled on 13 January.
Key Takeaways
- Johnson & Johnson and Intra-Cellular’s board agreed to a $14.6bn buyout, which would bring the health care giant the projected blockbuster Caplyta.
- Caplyta, already approved to treat schizophrenia and bipolar depression, will serve a larger patient base if major depressive disorder is added to its label
With the deal announcement, contingent on Intra-Cellular shareholders’ approval but already okayed by the company’s board, J&J predicted Caplyta eventually will yield peak annual sales of more than $5bn, topping the Street’s $3.5bn consensus prediction. “It’s going to lift our sales growth versus what is [projected] today in the analyst models, immediately until the rest of decade,” J&J CEO Joaquin Duato said during a same-day J.P. Morgan Healthcare Conference appearance. “It gives us the financial resiliency … to be able to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
